Incyte is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. It is focused on developing and selling drugs that inhibit specific enzymes associated with cancer and other diseases. The company's lead program is its JAK (Janus associated kinase) inhibitor program. Its first commercial product, Jakafi, is approved for treatment of polycythemia vera and myelofibrosis (two rare blood cancers) and graft-versus-host-disease in the US; partner Novartis markets the drug internationally. Another inhibitor drug, Iclusig, is marketed for certain forms of leukemia in Europe. Incyte has a number of product candidates in research and clinical development stages, partially through partnerships with other drugmakers, for various cancers, inflammatory ailments, and other conditions.